S 705 · in committee · significant
Innovation in Pediatric Drugs Act of 2025
- healthcare
What this bill does
- The FDA gains power to require pediatric studies on rare disease drugs (orphan drugs) to ensure safety and effectiveness for children.
- Drug manufacturers are affected and must conduct pediatric research or face FDA enforcement action.
- The NIH receives funding for pediatric research on rare diseases, with GAO tracking the bill's impact on drug development.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would requiring pediatric studies on orphan drugs affect the timeline and cost of bringing rare disease treatments to market for children?
- 02
What oversight mechanisms should the GAO use to measure whether this bill actually improves pediatric drug safety without discouraging manufacturers from developing treatments for rare diseases?
- 03
Which rare pediatric diseases lack adequate treatment options today, and how might mandatory study requirements change drug companies' willingness to develop therapies for them?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-RI
Jack Reed
Citizen cosponsors
0
In Congress
1/ 100
Senators cosponsoring
Introduced 2025-02-25
Joining the bill
Legislative timeline
2025-02-25 · senate · IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)
2025-02-25 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.